Clinical trials: suspended, in United States
Abdominal Aortic Aneurysms (AAA)
Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA
The goal of this clinical trial is to learn if the Fenestrated TREO Stent-Graft System works to treat abdominal aneurysms in adults.
- Trial name
- NCT07026877
- Testing
- Fenestrated TREO Stent Graft System
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Bolton Medical
Cancer
A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy
The goal of this clinical trial is to assess whether Shengbai Oral Formula is a viable option for treatment of fatigue, pain, and neutropenia in patients undergoing their third cycle of chemotherapy.
- Trial name
- NCT06706752
- Testing
- Shengbai Oral Formula
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sutter Health
Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Background: Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatment (relapse) in almost all people; MM may also not respond to initial treatment (refractory).
- Trial name
- NCT06876142
- Testing
- Mirdametinib, Sirolimus
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Opioid Use Disorder, Healthy Volunteers
Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Substance Use Disorder
Background: The purpose of this study is to understand how a type of brain stimulation, transcranial magnetic stimulation (TMS), may help those who use opioids such as heroin or methadone.
- Trial name
- NCT06577454
- Testing
- TMS (MagVenture MagPro 100 with MagOption)
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Mucosal Melanoma of the Head and Neck
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control…
- Trial name
- NCT04318717
- Testing
- Pembrolizumab, Hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06694454
- Testing
- azacytidine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Background: Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return.
- Conditions
- Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
- Trial name
- NCT05642195
- Testing
- Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Presbylarynx, Aspiration
Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort
A previous study completed in 2022 (NCT05158179) was conducted using cohorts of healthy controls, and adults with general laryngopharyngeal disorders.
- Conditions
- Presbylarynx, Aspiration, Spasmodic Dysphonia, Globus Pharyngeus
- Trial name
- NCT06078527
- Testing
- Cheung-Bearelly Aesthesiometer, Transnasal Laryngoscopy, Questionnaires
- Where
- United States
- Volunteers
- 505 people
- Sponsor
- University of California, San Francisco
DLBCL, Diffuse Large B Cell Lymphoma
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
This is a multicenter Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and an FDAapproved CAR-T product…
- Conditions
- DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
- Trial name
- NCT04855253
- Testing
- E7777, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostate Adenocarcinoma, PSA Failure
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back (recurrent) or has favorable risk and has not…
- Conditions
- Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma
- Trial name
- NCT04519879
- Testing
- Clinical Observation, Patient Observation, Questionnaire Administration
- Where
- 7 sites in United States
- Volunteers
- 133 people
- Sponsor
- City of Hope Medical Center
Gastric Outlet Obstruction
AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE
To investigate the safety and technical success of EUS-guided gastroenterostomy (EUS-GE) using the AXIOSTM lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant…
- Trial name
- NCT06174805
- Testing
- AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
- Where
- 10 sites in United States, Belgium and 4 more
- Volunteers
- 67 people
- Sponsor
- Boston Scientific Corporation
Progressive Glioblastoma, Recurrent Glioblastoma
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come…
- Trial name
- NCT06325683
- Testing
- Biopsy Procedure, Biospecimen Collection, Lomustine
- Where
- 325 sites in United States
- Volunteers
- 184 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05685602
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Neuropathic Pain
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain…
- Trial name
- NCT06980948
- Testing
- ST-503
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Sangamo Therapeutics
Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer
This phase I study assesses the safety, ultrasound visibility (conspicuity), and movement from normal position (migration) of the twinkling marker in patients with breast cancer that has spread to the axillary lymph nodes…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Resectable Breast Carcinoma
- Trial name
- NCT05547347
- Testing
- Magnetic Resonance Imaging, Mammogram, Ultrasound
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Pancreatic Cancer
TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer
This is a Phase I/II study evaluating the intraperitoneal delivery of TROP2 CAR/IL-15 TGFBR2 KO NK cells in combination with oral belzutifan (120 mg daily) for patients with recurrent, locally advanced, unresectable and…
- Trial name
- NCT07377526
- Testing
- TGFBR2 KO CAR27/IL-15 NK cells
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Prostasomes as Diagnostic Tool for Prostate Cancer Detection
Prostate cancer is the most frequently diagnosed cancer among men over 50 years old in Western societies, with an incidence that is steadily increasing in most countries.
- Trial name
- NCT03694483
- Testing
- Genetic analysis for the detection of prostasomes
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to…
- Conditions
- Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma
- Trial name
- NCT06568172
- Testing
- Biospecimen Collection, Cemiplimab, Computed Tomography
- Where
- 206 sites in United States, Australia and 1 more
- Volunteers
- 420 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma…
- Conditions
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT03604991
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 488 sites in United States
- Volunteers
- 278 people
- Sponsor
- National Cancer Institute (NCI)
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer…
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT01810913
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 342 sites in United States, Canada and 1 more
- Volunteers
- 613 people
- Sponsor
- National Cancer Institute (NCI)